Papers

Research literature with structured metadata.

Trials

Registered studies by status, phase, and compound.

Topics

Indications and themes psychedelics are researched for.

Compounds

Evidence across molecules with rich data.

Countries

Regulation, access, and research activity by region.

Stakeholders

Organizations shaping the space across research, policy, and funding.

People

Investigators, clinicians, and authors with mapped output.

Courses

Training programs and certifications across modalities.

Events

Conferences, workshops, and convenings by date and focus.

Results

Compare outcome data across trials and publications.

Research Snapshot

One-page overview of trials, participants, papers, and research networks.

Clinical Guidelines

Trial-anchored manuals and protocol guidance with competency mapping.

Research recaps

Monthly evidence summaries with key takeaways.

Map of research

Landscape view of trials, compounds, and outcomes.

Newsletter

Weekly or daily updates on trials, publications, analysis, and more.

Research Groups

Worldwide map of psychedelic research centres by region.

Road to Access

Science, regulation, and economics on the path to patient access.

Research Network

Interactive co-authorship map of psychedelic researchers.

Top papers

Find needles in the haystack of psychedelic research per topic.

AskBeta
Pricing

The intelligence layer for psychedelic research.

Company

  • About
  • Contact
  • Newsletter

Product

  • Feedback
  • Roadmap
  • Changelog
  • API
  • Partners
  • Clinical Guidelines

Legal

  • Privacy
  • Terms

© 2026 Blossom. All rights reserved.

Home/Research/Ibogaine/Substance Use Disorders (SUD)

Ibogaine for Substance Use Disorders (SUD)

54 papers and 3 clinical trials exploring ibogaine as a treatment for substance use disorders (sud).

CompoundIndole Alkaloid

Ibogaine

A unique indole alkaloid with complex pharmacology, investigated primarily for its capacity to interrupt substance use disorders and withdrawal.

Full Ibogaine profile
IndicationAmong the world’s largest preventable health burdens

Substance Use Disorders (SUD)

Addiction is one of the oldest hopes for psychedelic medicine, going back to LSD trials for alcoholism in the 1950s. Today psilocybin is the workhorse, with positive trials in alcohol, tobacco and cocaine use disorders, and the cross-substance signal is real. But the picture is mixed rather than settled: a major alcohol trial was null, the studies are small, and almost all of them struggle to keep patients unaware of whether they got the drug. This page is the hub; alcohol, opioid and tobacco use disorders have their own dedicated pages.

Full Substance Use Disorders (SUD) profile

Academic Research

54 papers
Open Accessindividual

Exploring the Use of Ibogaine in Opioid Recovery: Insights from Lived Experience

This qualitative case study (n=10) explored the experiences of opioid-dependent people in New Zealand who used ibogaine for detoxification. Participants described rapid withdrawal relief, better mood and less anxiety, and some sustained abstinence, but relapse still occurred and preparation, medical screening and post-treatment support were seen as important.

Published
May 22, 2026
Journal
Journal of Psychoactive Drugs
Authors
Walker, J., Deering, D., Unger, B. H.
Open Accessindividual

Oxa-noribogaine reduces alcohol drinking through aversion learning and by altering glutamatergic activity in the mPFC

This rat study found that the ibogaine-derived compound oxa-noribogaine reduced alcohol drinking and relapse-like drinking by strengthening learning from negative drinking outcomes and changing glutamatergic activity in the prefrontal cortex. It also appeared to match or exceed ibogaine’s effects without detectable motor or cardiac problems.

Published
March 31, 2026
Journal
Research Square
Authors
Meinhardt, M., Skorodumov, I., Walter, F., Akan, M., Buchborn, T., PRIEULT, Y. L., Urban, M., Spanagel, R., von Ammon, L., Hopf, C., Kalinichenko, L., Mueller, C., Winter, C., Hadar, R., Gül, A. Z., Massuda, B., Hildebrandt, M., Domi, E., Keshishian, A., Ciccocioppo, R., Sames, D., Havel, V., Woods, L., Beeson, A.
Paywallindividual

A qualitative analysis of participant expectations and experiences of psilocybin-assisted psychotherapy for methamphetamine use disorder

Participants in a pilot study of psilocybin‑assisted psychotherapy for methamphetamine use disorder found the intervention acceptable and reported that confronting vividly challenging psychedelic experiences—described as “leaning into the obstacle”—fostered new self‑understandings and shifts in relationships that reduced the salience of methamphetamine. A strong therapeutic alliance, characterised by concentrated attention and intersubjective intimacy, was seen as critical to these positive changes.

Published
December 22, 2025
Journal
Addiction
Authors
Brett, J., Lea, T., Knock, E., Albert, S., Acheson, L., Siefried, K. J., Job, S.
Open Accessindividual

The pharmacokinetics and pharmacodynamics of ibogaine in opioid use disorder patients

This pharmacokinetic study (n=14) on ibogaine (700mg/70kg) for opioid use disorder (OUD) finds significant variability in ibogaine clearance, strongly correlated with CYP2D6 genotype. Ibogaine plasma concentrations correlate with QTc prolongation and cerebellar effects, while neither ibogaine nor noribogaine correlate with the severity of opioid withdrawal symptoms.

Published
March 22, 2024
Journal
Journal of Psychopharmacology
Authors
Knuijver, T., Heine, R. T., Schellekens, A., Heydari, P., Lucas, L., Westra, S., Belgers, M., van Oosteren, T., Verkes, R. J., Kramers, C.
Open Accessindividual

Magnesium-ibogaine therapy in veterans with traumatic brain injuries

This observational study (n=30) evaluates ibogaine (up to 980mg/70kg) in combination with magnesium (1-2 hours before and 12 hours later) in male Special Operations Forces veterans with predominantly mild traumatic brain injury (mTBI). The study assessed changes in disability, PTSD, depression, and anxiety immediately and one month after treatment using various scales. Results show significant improvements in functioning and psychological symptoms with no serious adverse events.

Published
January 5, 2024
Journal
Nature Medicine
Authors
Cherian, K. N., Keynan, J. N., Anker, L., Faerman, A., Brown, R. E., Shamma, A., Keynan, O., Coetzee, J. P., Batail, J. M., Phillips, A., Bassa, N. J., Sahlem, G. L., Inzunza, J., Millar, T., Dickinson, J., Rol, C. E., Keller, J., Adamson, M., Kratter, I. H., Williams, N. R.
Paywallmeta

Main targets of ibogaine and noribogaine associated with its putative anti-addictive effects: A mechanistic overview

This review (2023) examines ibogaine as a potential treatment for substance use disorders (SUDs). The lack of randomised, controlled studies on its safety and efficacy and the elusive mechanisms of action have been barriers to clinical use. The review suggests that ibogaine and its metabolite, noribogaine (NOR), modulate multiple targets associated with SUDs, emphasizing a complex, multi-target approach to understanding its pharmacology.

Published
November 8, 2023
Journal
Journal of Psychopharmacology
Authors
Ona, G., Reverte, I., Rossi, G. N., Dos Santos, R. G., Hallak, J. E., Colomina, M. T., Bouso, J. C.

Clinical Trials

3 trials
CompletedPhase II

Ibogaine in the Treatment of Alcoholism: a Randomized, Double-blind, Placebo-controlled, Escalating-dose, Phase 2 Trial

The aim of the present study is to evaluate the safety, tolerability and efficacy of increasing doses of ibogaine in 12 alcoholic patients.

Started
October 1, 2021
Type
interventional
Blinding
none
Randomized
Yes
Registry ID
NCT03380728
CompletedPhase II

Preliminary Efficacy and Safety of Ibogaine in the Treatment of Methadone Detoxification

This Phase-II RCT (n=20) in Spain randomises methadone-maintained patients to fixed ibogaine (6×100 mg) or ascending ibogaine doses (100→600 mg across six administrations) given when opioid withdrawal appears to support methadone detoxification.

Started
October 28, 2020
Type
interventional
Blinding
quadruple
Randomized
Yes
Registry ID
NCT04003948
CompletedPhase II

The Efficacy of Ibogaine in the Treatment of Addiction; an open label, single fixed dose pilot-study of the efficacy of ibogaine in opioid-dependent subjects

This open-label, single-arm Phase II pilot study (n=12) assesses a single fixed oral dose of ibogaine (700mg/70kg) for reducing craving and opioid use in opioid-dependent patients with neuroimaging and electrophysiological secondary measures.

Started
November 10, 2014
Type
interventional
Blinding
none
Randomized
No
Registry ID
2014-000354-11

Explore further

Search all Ibogaine papers Search all Substance Use Disorders (SUD) trials Full Ibogaine profile Full Substance Use Disorders (SUD) profile